South America Non Alcoholic Steatohepatitis Biomarkers Market

ID: MRFR/HC/47964-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
South America Non-Alcoholic Steatohepatitis Biomarkers Market Research Report By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Others), By End User (Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035
South America Non Alcoholic Steatohepatitis Biomarkers Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)2.36%
2024 Market Size$ 15 Million
2025 Market Size$ 15.35 Million
2035 Market Size$ 19.39 Million
Key Players
Gilead Sciences
Intercept Pharmaceuticals
Echosens
Celerion
Genfit
Pfizer
Trends
  • Rising Prevalence of Obesity
  • Advancements in Biomarker Research
  • Regulatory Support for Biomarker Development
Opportunities
  • Government Initiatives and Funding
  • Increasing Awareness of Liver Health
  • Rising Incidence of Metabolic Disorders
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Type (USD Million)
      1. 4.1.1 Hepatic Fibrosis Biomarkers
      2. 4.1.2 Serum Biomarkers
      3. 4.1.3 Oxidative Stress Biomarkers
      4. 4.1.4 Apoptosis Biomarkers
      5. 4.1.5 Others
    2. 4.2 Chemicals and Materials, BY End User (USD Million)
      1. 4.2.1 Research Institutes and Academics
      2. 4.2.2 Diagnostic Centres
      3. 4.2.3 Pharmaceutical Companies and CROs
      4. 4.2.4 Hospitals and Clinics
      5. 4.2.5 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Gilead Sciences (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Intercept Pharmaceuticals (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Echosens (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Celerion (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Genfit (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Bristol-Myers Squibb (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Novartis (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Hepion Pharmaceuticals (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY END USER
    4. 6.4 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    5. 6.5 RESEARCH PROCESS OF MRFR
    6. 6.6 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    7. 6.7 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    8. 6.8 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    9. 6.9 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    10. 6.10 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
    11. 6.11 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
    12. 6.12 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
    14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Non Alcoholic Steatohepatitis Biomarkers Market Segmentation

South America Non Alcoholic Steatohepatitis Biomarkers Market By Type (USD Million, 2025-2035)

  • Hepatic Fibrosis Biomarkers
  • Serum Biomarkers
  • Oxidative Stress Biomarkers
  • Apoptosis Biomarkers
  • Others

South America Non Alcoholic Steatohepatitis Biomarkers Market By End User (USD Million, 2025-2035)

  • Research Institutes and Academics
  • Diagnostic Centres
  • Pharmaceutical Companies and CROs
  • Hospitals and Clinics
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.